Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tibotec Prezista Mortality Imbalance Due To Partially Blinded Trials – FDA Review

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA officials called the lack of deaths in the control arms of Tibotec’s Prezista trials "striking" and "out of the range of past experience," and attributed the anomaly to the partially blinded study design.

You may also be interested in...

Fuzeon Increased Pneumonia Incidence Likely A "Specious" Finding – FDA

The increased incidence of bacterial pneumonia seen with Roche/Trimeris’ Fuzeon may be an artifact of the design of the pivotal trails, FDA suggested in review documents for the HIV therapy.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

September 2010 Approvals






Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts